#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Joy Bessenger Email
SVP, Investor Relations and Corporate Strategy . IMV
How to contact Joy Bessenger
Join and see Joy's contact info for free!Current Roles
Employees:
38Revenue:
$20MAbout
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company?s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the reprogramming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV's lead candidate, DPX-Survivac, is a T cell activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently conducting three Phase 2 studies with Incyte and Merck assessing DPX-Survivac as a combination therapy in ovarian cancer and diffuse large B-cell lymphoma. For more information, please connect at: www.imv-inc.comIMV Address
130 Eileen Stubbs AveDartmouth, null